



## **Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids.**

Courtney B. Ferrebee, *Emory University*  
[Paul Dawson](#), *Emory University*

---

**Journal Title:** Acta Pharmaceutica Sinica B  
**Volume:** Volume 5, Number 2  
**Publisher:** Elsevier | 2015-03, Pages 129-134  
**Type of Work:** Article | Final Publisher PDF  
**Publisher DOI:** 10.1016/j.apsb.2015.01.001  
**Permanent URL:** <https://pid.emory.edu/ark:/25593/r8pmv>

---

Final published version: <http://dx.doi.org/10.1016/j.apsb.2015.01.001>


### **Copyright information:**

© 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Accessed December 15, 2019 2:27 PM EST



## REVIEW

# Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids


 Courtney B. Ferrebee<sup>a,b</sup>, Paul A. Dawson<sup>a,\*</sup>
<sup>a</sup>Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Emory University, Atlanta, GA 30322, USA

<sup>b</sup>Molecular Medicine Graduate Program, Wake Forest School of Medicine, Winston-Salem, NC 27153, USA

Received 19 December 2014; received in revised form 30 December 2014; accepted 4 January 2015

## KEY WORDS

 Bile acids;  
 Liver;  
 Intestine;  
 Transporters;  
 Lipid metabolism;  
 Energy homeostasis

**Abstract** The classical functions of bile acids include acting as detergents to facilitate the digestion and absorption of nutrients in the gut. In addition, bile acids also act as signaling molecules to regulate glucose homeostasis, lipid metabolism and energy expenditure. The signaling potential of bile acids in compartments such as the systemic circulation is regulated in part by an efficient enterohepatic circulation that functions to conserve and channel the pool of bile acids within the intestinal and hepatobiliary compartments. Changes in hepatobiliary and intestinal bile acid transport can alter the composition, size, and distribution of the bile acid pool. These alterations in turn can have significant effects on bile acid signaling and their downstream metabolic targets. This review discusses recent advances in our understanding of the inter-relationship between the enterohepatic cycling of bile acids and the metabolic consequences of signaling *via* bile acid-activated receptors, such as farnesoid X nuclear receptor (FXR) and the G-protein-coupled bile acid receptor (TGR5).

 © 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. Open access under [CC BY-NC-ND license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

*Abbreviations:* ACCII, acetyl-CoA carboxylase 2; APO, apolipoproteins; ASBT, apical sodium-dependent bile acid transporter; BSEP, bile salt export pump; CYP7A1, cholesterol 7 $\alpha$ -hydroxylase; DIO2, deiodinase 2; FAS, fatty acid synthase; FGF, fibroblast growth factor; FOXO1, forkhead box protein O1; FGFR4, fibroblast growth factor receptor 4; FXR, farnesoid X-receptor; G6Pase, glucose-6-phosphatase; GLP-1, glucagon-like polypeptide-1; HNF4 $\alpha$ , hepatocyte nuclear factor 4 alpha; IBABP, ileal bile acid binding protein; LDL, low density lipoprotein; NTCP, Na<sup>+</sup>-taurocholate transporting polypeptide; OATP, organic anion transporting polypeptide; OST, organic solute transporter; PEPCK, phosphoenolpyruvate carboxykinase; PGC1 $\alpha$ , peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PPAR, peroxisome proliferator-activated receptor; SHP, small heterodimer partner; SREBP1c, sterol regulatory element binding protein-1c; T4, thyroid hormone; TGR5, G-protein-coupled bile acid receptor; VLDL, very low density lipoprotein

\*Corresponding author. Tel.: +1 404 7277083.

 E-mail address: [paul.dawson@emory.edu](mailto:paul.dawson@emory.edu) (Paul A. Dawson).


Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

 2211-3835 © 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. Open access under [CC BY-NC-ND license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

<http://dx.doi.org/10.1016/j.apsb.2015.01.001>

## 1. Introduction

Research over the past 80 years has yielded considerable insight into the role of bile acids in intestinal fat absorption, hepatic bile formation, and cholesterol homeostasis<sup>1</sup>. However more recently, it has become apparent that bile acids also serve as signaling molecules with metabolic effects that extend beyond their control of hepatobiliary and intestinal function<sup>1-3</sup>. This has generated considerable renewed interest in bile acids and their metabolism. Bile acids are steroid acids synthesized from cholesterol in the liver<sup>4</sup>. Following their synthesis, bile acids are secreted along with other biliary constituents into the small intestine. After functioning in the proximal intestine to promote nutrient digestion and absorption, bile acids travel down the length of the small intestine to the terminal ileum for absorption. The bile acids are then carried in the portal circulation back to the liver for uptake and re-secretion into bile. The process of intestinal absorption is very efficient and about 95% of the bile acids secreted into the small intestine are reclaimed. Those bile acids that escape absorption pass into the colon and can be eliminated in the feces. Specialized membrane transporters expressed on the apical and basolateral membranes of the hepatocyte and ileal enterocyte largely mediate the movement of charged plasma membrane-impermeant bile acids molecules across those cell barriers<sup>5</sup>. For hepatocytes, the major transporters are the Na<sup>+</sup>-taurocholate cotransporting polypeptide (NTCP; SLC10A1) and members of the organic anion transporting polypeptide (OATP) family (OATP1B1 and OATP1B3 in humans) on the sinusoidal membrane and the bile salt export pump (BSEP; ABCB11) on the canalicular membrane. For the ileal enterocyte, the major transporters are the apical sodium dependent bile acid transporter (ASBT; SLC10A2) on the brush border membrane and the heteromeric organic solute transporter alpha-beta (OST $\alpha$ -OST $\beta$ ; SLC51A, SLC51B) on the basolateral membrane<sup>6,7</sup>. In this paradigm, the ASBT and OST $\alpha$ -OST $\beta$  function as major gatekeepers for the intestinal compartment of the enterohepatic circulation of bile acids. However, in addition to being important for determining the fate of bile acids, *i.e.*, their absorption *versus* their excretion in the feces, bile acid uptake by the ileal enterocyte is important for gut-liver signaling and regulation of bile acid synthesis. During transit through the ileal enterocyte, bile acids activate the nuclear receptor farnesoid X nuclear receptor (FXR), and increase transcription of the polypeptide hormone, fibroblast growth factor-19 (mouse ortholog, FGF15). FGF15/19 is then released from the intestine and travels to the liver where it signals through its cell surface receptor, a complex of the fibroblast growth factor receptor-4 (FGFR4) and its protein co-receptor  $\beta$ -Klotho, to repress transcription of the microsomal cytochrome P450 gene cholesterol 7 $\alpha$ -hydroxylase (*Cyp7a1*) and inhibit hepatic bile acid synthesis<sup>8</sup>. Although a major function of the FXR-FGF15/19 pathway is to control hepatic bile acid synthesis and prevent bile acid accumulation, there is also evidence that this pathway can impact lipid, carbohydrate, and energy metabolism<sup>9-11</sup>. Bile acids are being viewed increasingly as metabolic regulators, and this has opened the door to targeting bile acid-related pathways as potential therapies for nonalcoholic fatty liver disease and other metabolic disorders<sup>2,12,13</sup>. This review focuses on the crosstalk between the enterohepatic cycling of bile acids and the metabolic consequences of signaling *via* bile acid-activated receptors such as FXR and TGR5 (the G-protein-coupled bile acid receptor) (Fig. 1).



**Figure 1** Bile acid (BA) mediated activation of FXR and TGR5 pathways in the enterohepatic circulation and systemic tissues. In the hepatocyte, bile acid activation of FXR increased SHP expression, which can decrease expression of SREBP1c and lipogenesis. Hepatic SHP activation can also lead to decreased expression of G6Pase and PEPCK, and reduced gluconeogenesis. FXR regulation of lipid metabolism and transport may involve decreasing the expression of fatty acid synthase (FAS) and apolipoproteins such as ApoA1, and inducing PPAR $\alpha$ . FXR also controls bile acid transport by titrating the expression of NTCP (import) and BSEP (export) in the hepatocyte, and ASBT, OST $\alpha$ -OST $\beta$ , and IBAPP in ileal enterocytes. FXR stimulation in the intestine increases the production of FGF15/19, which can have systemic effects on acetyl-CoA carboxylase 2 (ACCII), SREBP1c and PPAR expression in white adipose. TGR5 stimulation in the brown adipose (and skeletal muscle, not pictured) can stimulate deiodinase (DIO2) expression, which leads to increased energy expenditure and metabolic rate. TGR5 activation in the colon (not shown) can also increase release of glucagon-like polypeptide-1 (GLP-1), leading to improved glucose disposition and increased insulin sensitivity.

## 2. Bile acid signaling pathways and metabolic regulation

### 2.1. Effects of hepatic FXR on metabolism

FXR was established as the primary bile acid nuclear receptor in 1999<sup>14,15</sup>. Although expressed in a variety of tissues such as white adipose, kidney and adrenal, FXR is expressed at highest levels in the liver and intestine and is best known for its role in maintaining bile acid homeostasis. This is accomplished in part by regulating the expression of bile acid transporters such as BSEP, OST $\alpha$ -OST $\beta$  and NTCP, and the expression of transcription factors such as small heterodimer partner (SHP), which is involved in the repression of CYP7A1. However, FXR also regulates the metabolism of other lipids, either directly or indirectly *via* its effects on bile acid metabolism. For example, FXR-mediated repression of hepatic bile acid synthesis also reduces the catabolism and elimination of cholesterol as a result of the cholesterol-bile acid precursor-product relationship<sup>4,16</sup>. Through such direct or indirect mechanisms, FXR has been associated with a myriad of effects on lipid metabolism. With regard to triglyceride metabolism, activation of FXR by the natural agonist cholic acid reduces hepatic triglyceride levels by decreasing sterol regulatory element binding protein-1c (SREBP1c)-stimulated lipogenesis in a mechanism involving SHP<sup>17</sup>. These effects of FXR on SREBP1c expression and triglyceride synthesis may be mediated in part by the

peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1 $\alpha$ )<sup>18</sup>. In humans, FXR can induce expression of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ), a master regulator of fatty acid metabolism<sup>19</sup>. In this way, activation of FXR could lead to increased lipolysis, increased fatty acid oxidation, and decreased lipogenesis. FXR's list of actions also encompasses effects on lipoprotein metabolism<sup>20</sup>. For example, studies have shown that FXR can affect plasma lipid transport by decreasing expression of the apolipoproteins (Apo) as ApoAI and ApoCII, and increasing ApoCIII; FXR also induces expression of the very low density lipoprotein (VLDL) receptor to contribute to lipoprotein clearance<sup>21–25</sup>.

In addition to its role in lipid metabolism, FXR may regulate glucose metabolism<sup>26,27</sup>. FXR induction of SHP expression can decrease expression of hepatocyte nuclear factor-4 alpha (HNF4 $\alpha$ ) targets such as the gluconeogenic genes glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK)<sup>28</sup>. This may be accomplished in part by FXR modulation of hepatic PGC1 $\alpha$  to repress expression of these gluconeogenic genes<sup>29</sup>. Activation of FXR also stimulates expression of pyruvate dehydrogenase kinase, which may further suppress glycolysis and enhance fatty acid oxidation<sup>30</sup>. Finally, activation of Akt and effects on insulin secretion and signaling by FXR suggest that multiple pathways may be mediating its effects on glucose metabolism<sup>31</sup>.

## 2.2. Effects of intestinal FXR on metabolism

FXR activation in the intestine, specifically the ileum, has a major role in bile acid homeostasis. FXR regulates expression of the ileal bile acid transporters, ASBT, OST $\alpha$ -OST $\beta$  and the cytosolic ileal bile acid binding protein IBABP (FABP6)<sup>5</sup>. However in addition to control of bile acid flux and systemic exposure to bile acids, intestinally expressed FXR may affect metabolism *via* regulation of FGF15/19 production. Evidence indicates that the actions of FGF15/19 extend beyond its effects on bile acid metabolism, and include regulation of lipid and glucose metabolism<sup>11</sup>. For example, transgenic overexpression of FGF19 or treatment with recombinant FGF19 reduces adiposity and increases metabolic rate and levels of the satiety hormone leptin<sup>32</sup>. FGF19 has been shown to inhibit hepatic fatty acid synthesis by decreasing the expression of SREBP1c through indirect mechanisms<sup>33</sup>. It is also important to note that FGF19 can signal through FGF receptors in addition to FGFR4, and may act through these receptors in the central nervous system to alter lipid and glucose homeostasis<sup>34–36</sup>. Since many of these studies rely on use of exogenous recombinant FGF19, the question of whether these effects are physiological or pharmacological has been raised<sup>9</sup>. However, there is very strong genetic evidence from mouse models supporting endogenous FGF15's ability to elicit similar metabolic effects<sup>37,38</sup>. These studies suggest that FGF15 acts in parallel with insulin to maintain normal glycogen levels by using an alternate Ras-ERK-p90RSK pathway<sup>37</sup>. In addition, FGF15/19 negatively regulates PGC1 $\alpha$  and suppresses hepatic gluconeogenesis<sup>38</sup>. It has also been suggested that FGF15 may affect expression of forkhead box protein O1 (FOXO1), a regulator of gluconeogenesis<sup>39</sup>. Interestingly, *Fgfr4* deficiency or administration of FGFR4 antisense oligonucleotides improves hyperlipidemia, adiposity, and insulin resistance characteristic of fatty liver and diet-induced obesity, further supporting the hypothesis that FGF receptors in addition to FGFR4 are involved in the metabolic effects of FGF15/19<sup>40,41</sup>.


## 2.3. Effects of TGR5 on metabolism

TGR5 was identified as a bile acid-activated G-protein coupled receptor in 2003<sup>42</sup>. With the growing appreciation of bile acids as signaling molecules, considerable study is being directed towards understanding the physiological functions of TGR5<sup>43</sup>. For example, bile acid activation of TGR5 can regulate gallbladder filling, intestinal motility, and may have a role in bile acid-induced itch and the analgesia associated with cholestatic liver disease<sup>44–46</sup>. There are also metabolic effects associated with TGR5 signaling in brown adipose, muscle, and macrophages<sup>10</sup>. As with FXR, there is increasing interest in TGR5 as a potential therapeutic target for a variety of metabolic diseases<sup>12,13,47</sup>. For example, administration of the TGR5-selective synthetic agonist (INT-777) to mice attenuated diet-induced obesity and improved glucose tolerance<sup>48</sup>. The metabolic benefits may be due in part to increased metabolic rate and energy expenditure, secondary to TGR5-mediated increases in expression of deiodinase 2 (DIO2) and increased production of thyroid hormone (thyroxine, T4)<sup>49,50</sup>. These metabolic effects may also be mediated through bile acid activation of TGR5 on enteroendocrine L-cell in the distal small intestine and colon. In that mechanism, TGR5 signals to increase production and release of GLP-1, the incretin hormone that promotes insulin sensitivity, and thereby improves glucose disposition<sup>51,52</sup>. Therapies targeting GLP-1 are currently used to treat diabetes, and strategies that augment GLP-1 production, half-life, or activity may have benefit in other disorders such as hepatic steatosis and cardiac hypertrophy<sup>53</sup>. Finally, it should be noted that bile acids signal through other receptors and pathways in addition to FXR and TGR5, and additional research is needed to understand their contribution to the metabolic effects of bile acids<sup>2,3,43,54</sup>.

## 3. Metabolic effects associated with altered intestinal absorption of bile acids

### 3.1. Bile acid sequestrants and bile acid transporter inhibitors

Emerging research examining the effects bile acid sequestrants (bile acid binding resins) suggests a metabolic benefit associated with blocking intestinal absorption of bile acid beyond its well-characterized plasma cholesterol-lowering actions<sup>55</sup>. Bile acid sequestrants were originally used to treat hypercholesterolemia and bile acid malabsorption in the 1960s<sup>55,56</sup>. Disruption of the enterohepatic circulation of bile acids by blocking their intestinal absorption stimulates hepatic *de novo* bile acid synthesis from cholesterol. The hepatic demand for cholesterol is met by increasing hepatic cholesterol synthesis and plasma clearance of lipoproteins such as low density lipoprotein (LDL)<sup>57</sup>. Although not widely used to treat hypercholesterolemia after introduction of the HMG CoA reductase inhibitors (statins), bile acid sequestrants operating through this mechanism had shown benefit with regard to lowering plasma cholesterol levels and reducing cardiovascular disease in studies such as the Lipid Research Clinics Coronary Primary Prevention Trial<sup>58</sup>. However, in addition to their plasma cholesterol lowering properties, there is evidence that bile acid sequestrants can improve glycemic control, and the underlying mechanisms of action are being explored<sup>55–61</sup>. Various mechanisms have been thus far been implicated. Decreasing bile acid enterohepatic cycling will reduce the pool of bile acids available for micellar solubilization of lipids in the intestinal lumen, and is predicted to reduce lipid absorption in the proximal small intestine.



**Figure 2** Predicted regulatory and metabolic effects of blocking ileal apical membrane (*Asbt* null mice) versus ileal basolateral membrane (*Osta* null mice) bile acid transport. The arrows indicate the direction of predicted changes in *Asbt* null mice or *Osta* null mice relative to wild type mice for the indicated physiological processes or pathways.

Indeed, treatment with a bile acid sequestrant has been shown to increase the incorporation of sterols and fatty acids into bile and feces, and alter lipid metabolism through excretion<sup>62</sup>. In addition, by blocking the apical uptake of bile acid into the ileal enterocyte, bile acid sequestrants block activation of the FXR-FGF15/19 pathway. This will increase hepatic CYP7A1 expression and bile acid synthesis, altering the composition of the bile acid pool. In mouse models treated with a bile acid sequestrant, it has been proposed that the increased synthesis of bile acids *via* the CYP7A1 pathway increases entry of natural TGR5 agonists (such as cholic acid and cholic acid derivatives) into the systemic circulation. This leads to increased energy expenditure in muscle and brown adipose tissue<sup>50</sup>. Blocking intestinal absorption also increases the flux of bile acids into the colon and can increase the TGR5-mediated release of GLP-1, which would act to promote insulin sensitivity<sup>51,52</sup>. Not surprising, administration of a small molecule inhibitor of the ASBT has effects similar to those described for bile acid sequestrants. For example, ASBT inhibitors reduced LDL cholesterol levels in various animal models<sup>63–65</sup>. Triglyceride and glucose metabolism has also been studied in animal models treated with ASBT inhibitors<sup>66,67</sup>.

### 3.2. Knockout models of defective intestinal bile acid absorption

Although loss of either the ASBT or OST $\alpha$ -OST $\beta$  transporters impairs intestinal bile acid absorption, characterization of the *Asbt* and *Osta*-*Ost $\beta$*  null mice is beginning to reveal important phenotypic differences in bile acid homeostasis that could affect lipid and glucose metabolism<sup>68,69</sup>. For the parameters examined to date, the *Asbt* null mice display a similar metabolic phenotype to that described for treatment with bile acid sequestrants or ASBT inhibitors<sup>66</sup>. Inactivation of the ASBT increases hepatic CYP7A1 and also reduces SREBP1c, improving triglyceride metabolism. With induction of hepatic bile acid synthesis and an enhanced flux of bile acids into the colon, there is also the potential for increased activation of TGR5<sup>50,67</sup>. The phenotype of the *Osta* null model is more complicated. Bile acids are internalized by the ileocyte, but

cannot exit the cell due to loss of *Osta*. This leads to activation of the FXR-FGF15/19 pathway and subsequent repression of CYP7A1 expression and a decrease in bile acid synthesis<sup>7,68,70</sup>. Similar to the *Asbt* null model, there is a decrease in intestinal lipid absorption due to a reduction in the bile acid pool size. However, the potential for TGR5 activation is predicted to be less in the *Osta* null mice. Candidate mechanisms and predicted metabolic consequences of blocking ileal apical versus basolateral bile acid transport are summarized in Fig. 2.

### Acknowledgments

Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH, No. R01DK047987). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. Courtney B. Ferrebee was supported by a Research Supplement to Promote Diversity in Health Related Research from the NIH.

### References

- Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. *J Lipid Res* 2014;**55**:1553–95.
- de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. *Cell Metab* 2013;**17**:657–69.
- Kuipers F, Blocks VW, Groen AK. Beyond intestinal soap—bile acids in metabolic control. *Nat Rev Endocrinol* 2014;**10**:488–98.
- Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem* 2003;**72**:137–74.
- Dawson PA, Lan T, Rao A. Bile acid transporters. *J Lipid Res* 2009;**50**:2340–57.
- Wong MH, Oelkers P, Dawson PA. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. *J Biol Chem* 1995;**270**:27228–34.
- Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. The organic solute transporter  $\alpha$ - $\beta$ , *Osta*-*Ost $\beta$* , is essential for

- intestinal bile acid transport and homeostasis. *Proc Natl Acad Sci USA* 2008;**105**:3891–6.
8. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* 2005;**2**:217–25.
  9. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators—a critical appraisal. *Cell Metab* 2012;**16**:693–705.
  10. Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid receptor TGR5—connecting nutrition and metabolism. *Thyroid* 2008;**18**:167–74.
  11. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. *Genes Dev* 2012;**26**:312–24.
  12. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov* 2008;**7**:678–93.
  13. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* 2014;**11**:55–67.
  14. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. *Science* 1999;**284**:1365–8.
  15. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. *Science* 1999;**284**:1362–5.
  16. Gardès C, Chaput E, Staempfli A, Blum D, Richter H, Benson GM. Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in *Ldlr*<sup>-/-</sup> mice versus hamsters. *J Lipid Res* 2013;**54**:1283–99.
  17. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 2004;**113**:1408–18.
  18. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor- $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ) regulates triglyceride metabolism by activation of the nuclear receptor FXR. *Genes Dev* 2004;**18**:157–69.
  19. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor  $\alpha$  gene via activation of the farnesoid X receptor. *Mol Endocrinol* 2003;**17**:259–72.
  20. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. *J Lipid Res* 2012;**53**:1723–37.
  21. Gutierrez A, Ratliff EP, Andres AM, Huang X, McKeehan WL, Davis RA. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. *Arterioscler Thromb Vasc Biol* 2006;**26**:301–6.
  22. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. *Gastroenterology* 2003;**125**:544–55.
  23. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. *J Clin Invest* 2002;**109**:961–71.
  24. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. *Mol Endocrinol* 2001;**15**:1720–8.
  25. Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Dartel R, et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. *FEBS Lett* 2004;**566**:173–7.
  26. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. *J Clin Invest* 2006;**116**:1102–9.
  27. Prawitt J, Abdelkarim M, Stroev JH, Popescu I, Duez H, Velagapudi VR, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. *Diabetes* 2011;**60**:1861–71.
  28. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. *J Biol Chem* 2004;**279**:23158–65.
  29. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 2001;**413**:131–8.
  30. Savkur RS, Bramlett KS, Michael LF, Burris TP. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. *Biochem Biophys Res Commun* 2005;**329**:391–6.
  31. Renga B, Mencarelli A, Vavassori P, Brancalione V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. *Biochim Biophys Acta* 2010;**1802**:363–72.
  32. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. *Endocrinology* 2002;**143**:1741–7.
  33. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. *J Biol Chem* 2009;**284**:10023–33.
  34. Hsueh H, Pan W, Kastin AJ. Fibroblast growth factor 19 entry into brain. *Fluids Barriers CNS* 2013;**10**:32.
  35. Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, et al. FGF19 action in the brain induces insulin-independent glucose lowering. *J Clin Invest* 2013;**123**:4799–808.
  36. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaionde SG, Woods SC, Seeley RJ. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. *Endocrinology* 2013;**154**:9–15.
  37. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. *Science* 2011;**331**:1621–4.
  38. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1 $\alpha$  pathway. *Cell Metab* 2011;**13**:729–38.
  39. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. *J Biol Chem* 2009;**284**:11110–20.
  40. Yu XX, Watts LM, Manchem VP, Chakravarty K, Monia BP, McCaleb ML, et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. *PLoS One* 2013;**8**:e66923.
  41. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. *Diabetes* 2007;**56**:2501–10.
  42. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003;**278**:9435–40.
  43. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev* 2014;**66**:948–83.
  44. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. *Gastroenterology* 2013;**144**:145–54.
  45. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. *Mol Endocrinol* 2011;**25**:1066–71.
  46. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. *J Clin Invest* 2013;**123**:1513–30.
  47. Vassileva G, Hu W, Hoos L, Tetzloff G, Yang S, Liu L, et al. Gender-dependent effect of *Gpbar1* genetic deletion on the metabolic profiles of diet-induced obese mice. *J Endocrinol* 2010;**205**:225–32.
  48. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* 2009;**10**:167–77.
  49. Watanabe M, Houten SM, Matakaki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006;**439**:484–9.

50. Watanabe M, Morimoto K, Houten SM, Kaneko-Iwasaki N, Sugizaki T, Horai Y, et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. *PLoS One* 2012;7: e38286.
51. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. *Sci Rep* 2012;2:430.
52. Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. *Am J Physiol Gastrointest Liver Physiol* 2013;304:G371–80.
53. Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. *Am J Physiol Gastrointest Liver Physiol* 2012;302:G225–35.
54. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. *J Lipid Res* 2009;50:1509–20.
55. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple resins. *Curr Opin Lipidol* 2012;23:43–55.
56. Thompson WG. Cholestyramine. *Can Med Assoc J* 1971;104:305–9.
57. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. *Drugs* 1980;19:161–80.
58. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251:351–64.
59. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. *Clin Ther* 2007;29:74–83.
60. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. *Diabetes* 2007;56:239–47.
61. Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. *J Pharmacol Exp Ther* 2010;334:164–70.
62. Sugimoto-Kawabata K, Shimada H, Sakai K, Suzuki K, Kelder T, Pieterman EJ, et al. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. *J Lipid Res* 2013;54:1255–64.
63. Root C, Smith CD, Sundseth SS, Pink HM, Wilson JG, Lewis MC. Ileal bile acid transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. *J Lipid Res* 2002;43:1320–30.
64. West KL, Zern TL, Butteiger DN, Keller BT, Fernandez ML. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. *Atherosclerosis* 2003;171:201–10.
65. Bhat BG, Rapp SR, Beaudry JA, Napawan N, Butteiger DN, Hall KA, et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in *ApoE*<sup>-/-</sup> mice by SC-435. *J Lipid Res* 2003;44:1614–21.
66. Lundäsen T, Andersson EM, Snaith M, Lindmark H, Lundberg J, Östlund-Lindqvist AM, et al. Inhibition of intestinal bile acid transporter SLC10A2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. *PLoS One* 2012;7: e37787.
67. Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. *Am J Physiol Endocrinol Metab* 2012;302:E68–76.
68. Lan T, Rao A, Haywood J, Kock ND, Dawson PA. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. *J Hepatol* 2012;57:359–65.
69. Wheeler SG, Hammond CL, Jornayvaz FR, Samuel VT, Shulman GI, Soroka CJ, et al. *Osta*<sup>-/-</sup> mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity. *Am J Physiol Gastrointest Liver Physiol* 2014;306:G425–38.
70. Ballatori N, Fang F, Christian WV, Li N, Hammond CL. *Osta*-*Ostβ* is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. *Am J Physiol Gastrointest Liver Physiol* 2008;295:G179–86.